| Views | |
|---|---|
| Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU | 115 |
| April 2025 | May 2025 | June 2025 | July 2025 | August 2025 | September 2025 | October 2025 | |
|---|---|---|---|---|---|---|---|
| Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU | 12 | 0 | 3 | 3 | 3 | 12 | 1 |
| Views | |
|---|---|
| 2019_Ertaş_etal.pdf | 245 |
| 2019_Ertaş_etal.pdf | 6 |
